-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Lowers Price Target to $160

Benzinga·11/20/2026 15:28:31
Listen to the news
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and lowers the price target from $166 to $160.